Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says

MT Newswires Live07-10

Praxis Precision Medicines (PRAX) could see greater commercial upside from its relutrigine epilepsy program as the rare epilepsy market may support premium pricing for the therapy, RBC Capital Markets said in a Friday note.

The firm said discussions with management and a review of existing developmental and epileptic encephalopathy therapies suggest relutrigine could sustain a list price of about $450,000 to $650,000.

RBC said the higher price could result in stricter payer requirements and initially limit use to patients with more severe disease. Even so, the firm now projects relutrigine revenue of about $2.6 billion by 2035, above the consensus estimate of about $2.45 billion.

The firm also said management has not yet decided the path forward for vormatrigine following the recent POWER1 setback, although it continues to evaluate the program.

RBC maintained its outperform rating on Praxis Precision Medicines and its $449 price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650803221?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650803221","market":"sh","top_or_hot":-1,"title":"Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> (PRAX) could see greater commercial upside from its relutrigine epilepsy program as the rare epilepsy market may support premium pricing for the therapy, RBC Capital Markets said in a Friday note.</p><p>The firm said discussions with management and a review of existing developmental and epileptic encephalopathy therapies suggest relutrigine could sustain a list price of about $450,000 to $650,000.</p><p>RBC said the higher price could result in stricter payer requirements and initially limit use to patients with more severe disease. Even so, the firm now projects relutrigine revenue of about $2.6 billion by 2035, above the consensus estimate of about $2.45 billion.</p><p>The firm also said management has not yet decided the path forward for vormatrigine following the recent POWER1 setback, although it continues to evaluate the program.</p><p>RBC maintained its outperform rating on Praxis Precision Medicines and its $449 price target.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> (PRAX) could see greater commercial upside from its relutrigine epilepsy program as the rare epilepsy market may support premium pricing for the therapy, RBC Capital Markets said in a Friday note.</p><p>The firm said discussions with management and a review of existing developmental and epileptic encephalopathy therapies suggest relutrigine could sustain a list price of about $450,000 to $650,000.</p><p>RBC said the higher price could result in stricter payer requirements and initially limit use to patients with more severe disease. Even so, the firm now projects relutrigine revenue of about $2.6 billion by 2035, above the consensus estimate of about $2.45 billion.</p><p>The firm also said management has not yet decided the path forward for vormatrigine following the recent POWER1 setback, although it continues to evaluate the program.</p><p>RBC maintained its outperform rating on Praxis Precision Medicines and its $449 price target.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650803221","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650803221","pubTimestamp":1783685933,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Praxis Precision Medicines  could see greater commercial upside from its relutrigine epilepsy program as the rare epilepsy market may support premium pricing for the therapy, RBC Capital Markets said in a Friday note.The firm said discussions with management and a review of existing developmental and epileptic encephalopathy therapies suggest relutrigine could sustain a list price of about $450,000 to $650,000.RBC said the higher price could result in stricter payer requirements and initially limit use to patients with more severe disease. Even so, the firm now projects relutrigine revenue of about $2.6 billion by 2035, above the consensus estimate of about $2.45 billion.The firm also said management has not yet decided the path forward for vormatrigine following the recent POWER1 setback, although it continues to evaluate the program.RBC maintained its outperform rating on Praxis Precision Medicines and its $449 price target.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IBRN":"iShares Neuroscience and Healthcare ETF","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","PRAX":"Praxis Precision Medicines, Inc.","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"加拿大皇家银行表示，Praxis Precision Medicines 的 Relutrigine 具有更大的商业优势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1.5,"IBRN":0.6},"content_text":"Praxis Precision Medicines (PRAX) could see greater commercial upside from its relutrigine epilepsy program as the rare epilepsy market may support premium pricing for the therapy, RBC Capital Markets said in a Friday note.The firm said discussions with management and a review of existing developmental and epileptic encephalopathy therapies suggest relutrigine could sustain a list price of about $450,000 to $650,000.RBC said the higher price could result in stricter payer requirements and initially limit use to patients with more severe disease. Even so, the firm now projects relutrigine revenue of about $2.6 billion by 2035, above the consensus estimate of about $2.45 billion.The firm also said management has not yet decided the path forward for vormatrigine following the recent POWER1 setback, although it continues to evaluate the program.RBC maintained its outperform rating on Praxis Precision Medicines and its $449 price target.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650803221","isCrawlerRequest":true}